A new publication referencing CJC-1295 appeared on May 20, 2026. The article, titled "Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications," was published in JBJS Reviews.
This publication is described as a structured narrative review. It addresses injectable peptides within the context of sports medicine, evidence, safety, and antidoping implications, according to the title.
CJC-1295 remains classified as an unapproved research compound. No dosing information, efficacy claims, or safety conclusions are stated here beyond the existence and title of this new review.
Readers interested in the broader context of CJC-1295 as a research compound can consult the compound overview for additional background.